Warning: The NCBI web site requires JavaScript to function. more...
Update on inflammatory breast cancer.
Lerebours F, Bieche I, Lidereau R.
Breast Cancer Res. 2005;7(2):52-8. Epub 2005 Jan 20. Review.
Related citations
Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants.
Kleer CG, van Golen KL, Merajver SD.
Breast Cancer Res. 2000;2(6):423-9. Epub 2000 Jul 11. Review.
Defining the molecular biology of inflammatory breast cancer.
Charafe-Jauffret E, Tarpin C, Viens P, Bertucci F.
Semin Oncol. 2008 Feb;35(1):41-50. Review.
Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry.
Zell JA, Tsang WY, Taylor TH, Mehta RS, Anton-Culver H.
Breast Cancer Res. 2009;11(1):R9. Epub 2009 Feb 19.
Molecular determinants of the inflammatory breast cancer phenotype.
Houchens NW, Merajver SD.
Oncology (Williston Park). 2008 Dec;22(14):1556-61; discussion 1561, 1565-8, 1576.
High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer.
Sawaki M, Ito Y, Akiyama F, Tokudome N, Horii R, Mizunuma N, Takahashi S, Horikoshi N, Imai T, Nakao A, Kasumi F, Sakamoto G, Hatake K.
Breast Cancer. 2006;13(2):172-8.
Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin.
Ben Hamida A, Labidi IS, Mrad K, Charafe-Jauffret E, Ben Arab S, Esterni B, Xerri L, Viens P, Bertucci F, Birnbaum D, Jacquemier J.
BMC Cancer. 2008 Jan 29;8:28.
Relapse-free survival in breast cancer patients is associated with a gene expression signature characteristic for inflammatory breast cancer.
Van Laere S, Beissbarth T, Van der Auwera I, Van den Eynden G, Trinh XB, Elst H, Van Hummelen P, van Dam P, Van Marck E, Vermeulen P, Dirix L.
Clin Cancer Res. 2008 Nov 15;14(22):7452-60.
Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature.
Bièche I, Lerebours F, Tozlu S, Espie M, Marty M, Lidereau R.
Clin Cancer Res. 2004 Oct 15;10(20):6789-95.
Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.
Adv Exp Med Biol. 2007;608:1-22. Review.
Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells.
Robertson FM, Simeone AM, Mazumdar A, Shah AH, McMurray JS, Ghosh S, Cristofanilli M.
J Exp Ther Oncol. 2008;7(4):299-312.
What progress have we made in managing inflammatory breast cancer?
Dawood S, Cristofanilli M.
Oncology (Williston Park). 2007 May;21(6):673-9; discussion 679-80, 686-7. Review.
Pathologic aspects of inflammatory breast cancer: part 2. Biologic insights into its aggressive phenotype.
Gong Y.
Semin Oncol. 2008 Feb;35(1):33-40. Review.
Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling.
Van Laere SJ, Van den Eynden GG, Van der Auwera I, Vandenberghe M, van Dam P, Van Marck EA, van Golen KL, Vermeulen PB, Dirix LY.
Breast Cancer Res Treat. 2006 Feb;95(3):243-55. Epub 2005 Oct 27.
Two prognostic groups of inflammatory breast cancer have distinct genotypes.
Lerebours F, Bertheau P, Bieche I, Plassa LF, Champeme MH, Hacene K, Toulas C, Espie M, Marty M, Lidereau R.
Clin Cancer Res. 2003 Sep 15;9(11):4184-9.
Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis.
Van Laere S, Van der Auwera I, Van den Eynden GG, Fox SB, Bianchi F, Harris AL, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY.
Breast Cancer Res Treat. 2005 Oct;93(3):237-46.
Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer.
Van den Eynden GG, Van Laere SJ, Van der Auwera I, Merajver SD, Van Marck EA, van Dam P, Vermeulen PB, Dirix LY, van Golen KL.
Breast Cancer Res Treat. 2006 Feb;95(3):219-28. Epub 2005 Oct 22.
Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding.
Van Laere SJ, Van der Auwera I, Van den Eynden GG, Elst HJ, Weyler J, Harris AL, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY.
Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3249-56.
Molecular biology of inflammatory breast cancer: applications to diagnosis, prognosis, and therapy.
Wu M, Merajver SD.
Breast Dis. 2005-2006;22:25-34. Review.
Molecular targets for treatment of inflammatory breast cancer.
Yamauchi H, Cristofanilli M, Nakamura S, Hortobagyi GN, Ueno NT.
Nat Rev Clin Oncol. 2009 Jul;6(7):387-94. Epub 2009 May 26. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on